DiaMedica Therapeutics Inc. (DMAC), a clinical stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, announced it has concluded a $11.8 million private placement to accredited investors.
The company sold approximately 4.7 million shares at a price of $2.50 per share- a 10% premium over the per-share closing price on June 25, 2024, with net proceeds accounting for $11.7 million.
This financial boost has significantly impacted their pro forma cash and investments.
As of March 31, 2024, DiaMedica reported cash, cash equivalents, and short-term investments totaling $46.7 million. However, on a pro forma basis, including the estimated $11.7 million in net proceeds from the private placement, their cash and investments would have reached $58.2 million.
DMAC has traded in a range of $1.93 to $4.4 in the last 1 year. As of pre-market, the stock is at $3.19, up 8.14%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.